Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Lewis, D. J.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; Scarfò, L.; Munir, T.; Lech-Marańda, E.; Hoffmann, M.; Ujjani, C. S.; Fakhri, B.; Wang, M. L.; Izutsu, K.; Nagai, H.; Tam, C. S.; Seymour, J. F.; Rhodes, J. M.; Vose, J. M.; McKinney, M.; Gerson, J. N.; Barve, M. A.; Kuss, B. J.; Koh, Y.; Gao, W.; Ruppert, A. S.; Walgren, R. A.; Tsai, D. E.; Nair, B.; Bao, K.; Mato, A. R.; Cheah, C. Y. |
| Abstract Title: | Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 557 |
| End Page: | 560 |
| Language: | English |
| ACCESSION: | WOS:000893223200229 |
| DOI: | 10.1182/blood-2022-159123 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
